Full-Time

Principal Software Engineer

Unified Lab Management

Updated on 8/7/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
LLM
Agile
Python
ERP
Data Science
Inventory Management
SQL
Machine Learning
Java
RDBMS
C#
REST APIs
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Engineering, Information Technology, or a related field.
  • A degree in Computer Science, Information Systems, Engineering, or Life Sciences.
  • Twelve to eighteen years of experience.
  • Extensive experience designing, configuring, and coding software, including custom development and commercial software packages using application programming interfaces, within an Agile environment.
  • Experience with integration standards including Web Services, SOAP, and REST.
  • Skill in object-oriented design and development and semantic web standards.
  • Experience with Java, Python, and Pipeline Pilot; C# is a plus.
  • Strong database management experience with SQL relational database management systems and SPARQL.
  • Understanding of business, manufacturing, and laboratory systems in the pharmaceutical industry and their integration through applicable standards.
  • Understanding of computer system validation and the software development lifecycle in biotech manufacturing and laboratory areas.
  • Strong leadership and project management skills.
  • Experience leading large matrixed teams and developing technology professionals.
  • Experience implementing strategic roadmaps and driving transformation initiatives using Scaled Agile methodology.
  • Strong collaboration and communication skills with cross-functional teams, business collaborators, and executives.
  • Ability to learn new software, troubleshoot, and apply critical-thinking techniques.
  • Experience building productive working relationships with business clients.
Responsibilities
  • Serve as a technical leader across multiple teams.
  • Coach mid-level and senior software development engineers.
  • Drive architectural decisions across multiple projects.
  • Maintain technical excellence and scalability in products.
  • Design, develop, and implement information systems solutions for end-to-end digitization of lab experimentation, simulations, and electronic recipe management across Operations.
  • Engage with business users to analyze business needs, identify technology solutions, and capture and document designs guided by Agile development best practices.
  • Collaborate with Information Systems Architects and System Owners to implement integrated solutions across PLM, ERP, MES, and the Enterprise Data Lake.
  • Perform hands-on development of technology solutions, including configuration of commercial software and extensions and integrations.
  • Represent the software development team in cross-functional leadership meetings.
  • Serve as lead Solution Engineer and oversee external contractors and consultants.
  • Review project deliverables throughout development for quality, traceability to requirements, and adherence to quality management plans and standards.
  • Participate in Information Systems quality validation reviews.
  • Oversee the backlog of requirements and user stories.
  • Collaborate with Platform Owners, Product Owners, Service Owners, and delivery teams to ensure delivery matches commitments, address critical issues, and facilitate communication when service commitments are unmet.
  • Ensure compliance with quality and GxP requirements in technology services, monitor emerging technologies and trends for platform growth, and maintain alignment with strategy, compliance, and regulatory requirements.
Desired Qualifications
  • Experience integrating solutions with enterprise resource planning and manufacturing execution system platforms.
  • Experience with Big Data integration and analytics.
  • Expertise with laboratory solution offerings including electronic laboratory notebooks, inventory management, manufacturing execution systems, and scientific analysis tools.
  • Five to eight years of domain knowledge in health or life sciences combined with Information Technology.
  • Understanding and applied experience in laboratory informatics and cross-functional data harmonization.
  • Knowledge of vendors' software strategies and competing solutions, with the ability to translate them into changing business needs and maximize software investments.
  • Experience managing a globally distributed enterprise application platform.
  • Leadership experience in a highly regulated pharmaceutical or technology organization, including compliance with industry regulations and GxP software validation methodologies.
  • Experience directing solution design, business-process redesign, and software implementation in a drug-development laboratory or commercialization environment.
  • Understanding of FDA regulations governing computer system validation and operation in biotech manufacturing and laboratory areas.
  • Experience using and adopting the Scaled Agile Framework.
  • Understanding of ITIL processes and implementation.
  • Established business partnerships and Information Systems governance practices involving senior business stakeholders.
  • Experience managing vendor relationships and external partners or consultants.
  • Strong analytical, critical-thinking, and decision-making abilities.
  • Experience working effectively in a fast-paced, dynamic environment.
  • Extensive experience in the software development lifecycle.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion on August 5, 2026.
  • Repatha grew 37%, Evenity 38%, and Uplizna 90% in Q2 2026.
  • MariTide entered broad Phase 3 testing, including switching studies from semaglutide and tirzepatide.

What critics are saying

  • FDA proposed Tavneos withdrawal on April 30, 2026, threatening roughly $600 million annual sales.
  • Enbrel sales fell 4% in Q2 2026 as Medicare Part D price setting bit.
  • AMG 513 ended, AMG 193 ended, and MariTide waits until 2027 data.

What makes Amgen unique

  • Amgen’s six growth drivers produced nearly 70% of Q2 2026 product sales.
  • Repatha, Evenity, and Uplizna deliver double-digit growth across cardiovascular, bone, and rare-disease markets.
  • Amgen generated $3.5 billion free cash flow in Q2 2026, funding R&D and dividends.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

PR Newswire
Aug 4th, 2026
Amgen reports 10% revenue growth to $10.1B in Q2 2026, driven by 26% surge in six key growth products

Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.

Yahoo Finance
Jul 7th, 2026
Amgen wins Enbrel price cap reprieve as Class II recalls raise quality concerns

Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.

Yahoo Finance
Jun 30th, 2026
NEJM retracts trial behind Amgen's $459M Tavneos as FDA probes data changes

The New England Journal of Medicine has retracted the 2021 clinical trial that supported approval of Amgen's Tavneos, a treatment for ANCA-associated vasculitis that generated $459 million in sales last year. The retraction followed an FDA investigation revealing that results from nine patients were altered after the study database was finalised, whilst some researchers had been unblinded. The FDA alleges the original data showed no statistically significant difference between Tavneos and existing treatments, but subsequent changes made the drug appear more effective. The agency proposed withdrawing Tavneos from the US market in April, whilst European regulators have also recommended removal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, continues selling Tavneos and has requested an FDA hearing. The company says it is engaging independent researchers to reanalyse the data.

Yahoo Finance
Jun 23rd, 2026
Amgen faces $20M–$60M damages after Delaware jury finds willful patent infringement

A Delaware jury ruled in June 2026 that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding Harbour $20.2 million in damages with the possibility of tripling that amount to $60.6 million. Whilst the verdict raises questions about Amgen's antibody discovery platforms and intellectual property exposure, the potential damages appear modest against Amgen's $37.1 billion to $38.5 billion revenue guidance. The ruling comes as Amgen received European Commission approval for IMDYLLTRA for extensive stage small cell lung cancer, supporting its oncology innovation narrative. Analysts project Amgen will reach $40.1 billion in revenue and $9.9 billion in earnings by 2029, requiring 2.5 per cent annual revenue growth. The patent dispute may prompt reassessment of whether Amgen can scale high-margin launches without increased legal risk.